FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Manzo Louis					2. Issuer Name and Ticker or Trading Symbol CAPRICOR THERAPEUTICS, INC. [ CAPR ]								(Check	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner				
(Last)	(First	`	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/31/2022									Officer (give title below)			Other (specify below)	
C/O CAPRICOR THERAPEUTICS, INC. 10865 ROAD TO THE CURE, SUITE 150					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
(Street) SAN DIEGO CA 92121													Form filed	d by More	than O	ne Reportin	g Person	
(City)	(State	e) (a	Zip)															
		T	able I - No	n-Deriva	ative S	ecuri	ties Ac	quired, D	isp	osed o	f, or Be	enefic	cially Ow	ned				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr.		rities Acquired (A) or ed Of (D) (Instr. 3, 4 and 5			5. Amount Securities Beneficially Following I	y Owned Reported	Form:	lirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A (D	() or ()	Price	Transaction(s) (Instr. 3 and 4)				(instr. 4)
Common Stock 03/3				03/31/2	1/2022		M		27,904		A	\$1.39	27,904			D		
Common Stock 03/3				03/31/2	31/2022			F <sup>(1)</sup>		11,309		D	\$3.43(1)	16,595			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ise (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code	Transaction Code (Instr.		mber of ative ities ired (A) sposed of estr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount Securities Underlyi Derivative Security 3 and 4)		erlying	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	ve O es F ially D or ng (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(A) (D) Date Expiration Date Title Amount or Number of Shares		Transaction(s) (Instr. 4)		<u>'</u>							
Stock Option (Right to Buy)	\$1.39 <sup>(2)</sup>	03/31/2022		M			15,455	(3)	04	/27/2022	Commo Stock		15,455(2)	\$0	0		D	
Stock Option (Right to Buy)	\$1.39 <sup>(4)</sup>	03/31/2022		М			12,449	(5)	04	/27/2022	Commo		12,449(4)	\$ <mark>0</mark>	0		D	

## Explanation of Responses:

- 1. Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on March 31, 2022 of \$3.43. The options would otherwise expire on April 27, 2022, pursuant to their terms.
- 2. This option was granted on April 27, 2012 and was previously reported as covering 154,555 shares at an exercise price of \$0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to \$1.39 per share that occurred on February 12, 2020.
- 3. The shares vested 1/48th of the first day of each month, commencing May 1, 2012.
- 4. This option was granted on April 27, 2012 and was previously reported as covering 124,491 shares at an exercise price of \$0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to \$1.39 per share that occurred on February 12, 2020.
- 5. The shares vested immediately.

/s/ Linda Marban, Attorney-in-

Fact

\*\* Signature of Reporting Person

04/01/2022 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.